What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals, Inc. is a Nasdaq-listed commercial-stage biopharmaceutical company focused on molecularly defined cancers and fibrotic diseases. Two products anchor the business: Revuforj, an oral menin inhibitor sold directly by Syndax, and Niktimvo, an anti-CSF-1R antibody commercialized with Incyte under a profit-sharing collaboration. The company’s official investor profile describes a business transitioning from development-stage biotechnology into a revenue-producing oncology franchise.
Approved products define the company today
Revuforj received its first U.S. approval in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation. In October 2025, the FDA expanded the label to susceptible NPM1-mutated relapsed or refractory acute myeloid leukemia in patients aged one year and older who have no satisfactory alternative. Niktimvo was approved in August 2024 for chronic graft-versus-host disease after failure of at least two prior systemic therapies in qualifying adult and pediatric patients. Those labels give Syndax two distinct commercial engines: a targeted leukemia medicine and a macrophage-directed therapy for a severe transplant complication.
| Identity item | Current position | Analytical importance |
|---|---|---|
| Reporting structure | One operating and reportable segment | Product franchises matter economically, but they are not separate GAAP segments. |
| Revuforj | Direct U.S. product sales | Syndax controls commercialization and records net product revenue. |
| Niktimvo | Incyte-led commercialization with 50% U.S. profit share | Reported collaboration revenue is not the same as total Niktimvo net sales. |
| Development focus | Hematologic malignancies, cGVHD, IPF, myelofibrosis and targeted lung cancer | Pipeline breadth is increasing, but clinical and regulatory concentration remains high. |
How does Syndax make money from Revuforj and Niktimvo?
Syndax has two revenue mechanisms with very different economics. Revuforj is a conventional product-sales model: specialty distributors and customers buy the drug, Syndax records net product revenue after rebates, discounts and returns, and the company bears manufacturing, medical-affairs and commercial costs. Niktimvo follows a collaboration model. Incyte records U.S. net sales and commercial expenses, and Syndax recognizes its share of collaboration profit. This difference is essential because a dollar of Niktimvo end-market sales does not translate into a dollar of Syndax revenue.
Direct sales and profit sharing create an asymmetric model
| Revenue stream | FY2025 amount | Q1 2026 amount | Economic driver |
|---|---|---|---|
| Revuforj product revenue | $124.8M | $48.9M | Prescription volume, net price, duration of therapy and label breadth. |
| Niktimvo collaboration revenue | $42.4M | $15.9M | Half of U.S. collaboration profit after eligible commercial costs. |
| Milestone, license and royalty revenue | $5.1M | Not material in Q1 2026 | Contractual events rather than recurring patient demand. |
Why the latest revenue mix matters
The 2025 Form 10-K also shows why accounting quality must be read carefully. Syndax recorded $172.4 million of FY2025 revenue, but partner-reported Niktimvo net sales were higher than the collaboration revenue in Syndax’s income statement. Adding both brands’ product sales would overstate Syndax’s economics.
What does Syndax’s latest quarter show?
The quarter ended March 31, 2026 was the clearest evidence yet that Syndax is moving from launch-stage volatility toward a more repeatable commercial cadence. According to the Q1 2026 earnings release, total revenue increased 224% year over year to $64.9 million. Revuforj revenue rose 144% year over year and 11% sequentially to $48.9 million, while total prescriptions increased 160% year over year and 13% from Q4 2025. Niktimvo generated $55.1 million of partner-reported net revenue, from which Syndax recognized $15.9 million of collaboration revenue.
Revenue is scaling faster than the expense base
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Total revenue | $64.9M | $20.0M | Commercial adoption drove a 224% increase. |
| Operating expenses | $99.1M | $103.8M | The cost base declined modestly despite two launches and broad development work. |
| Operating loss | $(34.2)M | $(83.8)M | Higher revenue narrowed the loss by $49.6M. |
| Net loss per share | $(0.48) | $(0.98) | Loss per share roughly halved year over year. |
| Operating cash used | $50.3M | $95.2M | Cash burn improved but remained substantial. |
Revuforj’s quarterly trajectory is the key commercial signal
Which turning points created today’s commercial-stage Syndax?
Syndax’s current model emerged from licensing, focused clinical development, collaboration financing and regulatory approvals. These steps moved it from a research company to a two-product commercial organization.
From licensed science to two approved medicines
-
2016Syndax completed its initial public offering and began trading on Nasdaq, creating public-market access to fund clinical development.
-
2017The company licensed the menin-inhibitor program that became revumenib from Vitae/Allergan, establishing the asset that now drives most revenue.
-
2021Syndax partnered axatilimab with Incyte, trading some economics for development resources and a scaled commercial partner.
-
August 2024Niktimvo won FDA approval for chronic graft-versus-host disease, validating CSF-1R inhibition in a commercial indication.
-
November 2024Revuforj became the first FDA-approved menin inhibitor for KMT2A-translocated relapsed or refractory acute leukemia.
-
October 2025The Revuforj label expanded into susceptible NPM1-mutated relapsed or refractory AML, materially enlarging the addressable population.
-
July 2026Syndax unveiled SNDX-4321 and SNDX-62122, signaling a shift from dependence on two legacy programs toward an internally refreshed pipeline.
That history explains today’s capital structure. Direct Revuforj commercialization requires sales and medical infrastructure; the Incyte collaboration lowers execution burden but caps Syndax’s Niktimvo economics. A $350 million Niktimvo-linked royalty financing in 2024 provided non-dilutive cash at the cost of a long-duration sales-linked obligation.
What gives Syndax an advantage in targeted oncology and fibrosis?
Syndax’s advantage comes from differentiated biology, regulatory timing and specialist access—not scale. Revuforj’s first-mover position created clinical familiarity and label precedent. Niktimvo targets macrophages through CSF-1R, differing from established cGVHD therapies. The company’s official pipeline extends those biological platforms into earlier-line disease and new fibrotic settings.
Evidence, label breadth and specialist access form the moat
| Strategic factor | Syndax position | Pressure point |
|---|---|---|
| Menin-inhibitor leadership | Revuforj was first approved in KMT2A-translocated leukemia and has adult-plus-pediatric labels. | Komzifti competes in adult NPM1-mutated relapsed or refractory AML, and more menin inhibitors are in development. |
| Mechanistic differentiation | Niktimvo blocks CSF-1R and targets macrophage-driven fibrosis. | Jakafi, Rezurock and Imbruvica already compete in cGVHD treatment pathways. |
| Commercial focus | Rare leukemia and transplant specialists create a concentrated call point. | Small eligible populations make every diagnosis, referral and access decision important. |
| Clinical expansion | Frontline, maintenance and fibrotic-disease studies can widen use. | Negative or delayed trials would leave value concentrated in current labels. |
The moat is credible but still evidence-dependent
How financially strong is Syndax?
Syndax has meaningful liquidity but is not yet self-funding. The March 31, 2026 Form 10-Q reported $130.9 million of cash and cash equivalents plus $221.2 million of short-term investments. Against that $352.1 million liquidity position, the company used $50.3 million of operating cash in Q1 2026. Cash equaled about seven times Q1 operating burn, though this is not formal runway guidance because revenue, working capital and development costs can change sharply.
Cash is substantial, but the royalty obligation changes leverage
| Financial item | Amount / period | What it means |
|---|---|---|
| Cash and short-term investments | $352.1M at March 31, 2026 | Funds commercialization and clinical programs without immediate dependence on new equity. |
| Royalty-financing liability | $344.0M long-term at March 31, 2026 | A sales-linked obligation tied to Niktimvo economics; economically meaningful even though it is not conventional bank debt. |
| Total liabilities | $431.0M at March 31, 2026 | The royalty liability is the dominant balance-sheet obligation. |
| Stockholders’ equity | $41.6M at March 31, 2026 | Accumulated losses and financing structure keep book equity comparatively thin. |
| FY2026 R&D plus SG&A guidance | About $400M, excluding about $50M of stock compensation | The expense hurdle to profitability remains high even as revenue scales. |
Expense architecture explains the path to profitability
FY2025 R&D expense was $258.8 million and SG&A was $179.7 million, compared with only $7.0 million of cost of product sales. Manufacturing cost is not the main constraint; clinical development and organizational scale are. In Q1 2026, R&D declined to $58.8 million and SG&A to $37.6 million while revenue expanded. The FY2025 results package states that existing cash, anticipated product revenues and interest income are expected to fund operations to profitability, but that outcome still depends on sustained product uptake and disciplined investment.
Which pipeline catalysts could reshape the business?
The most valuable opportunities can reduce concentration, extend product duration or move approved mechanisms into larger settings. Syndax is testing revumenib earlier in leukemia and axatilimab in newly diagnosed cGVHD and idiopathic pulmonary fibrosis. Two programs added in July 2026 extend the pipeline beyond the current brands.
Late-stage readouts can change the revenue ceiling
New programs diversify scientific risk but increase spending choices
At its July 14, 2026 R&D event, management positioned SNDX-4321 and SNDX-62122 as the next pipeline layer. This adds optionality but raises capital-allocation questions: early-stage EGFR and menin research competes with commercialization, label expansion and cash preservation. Ideally, current product growth funds later-stage trials before new programs become major cash consumers.
Who owns Syndax stock, and what does governance signal?
Syndax has one-share, one-vote stock rather than founder-controlled dual classes, making board quality, institutional ownership and incentives especially important. The 2026 proxy statement reported several large institutional holders and meaningful, but not controlling, management ownership. This is a governance profile in which strategy is influenced through board oversight and institutional engagement rather than a single controlling shareholder.
Ownership is concentrated among institutions, not insiders
| Holder or group | Beneficial ownership | Proxy-date stake | Why it matters |
|---|---|---|---|
| Kynam Capital Management | 8.52M shares | 9.6% | Largest disclosed holder, giving one external investor a meaningful economic voice. |
| BlackRock | 6.74M shares | 7.6% | Large institutional ownership increases the importance of governance and capital-allocation discipline. |
| Goldman Sachs | 5.58M shares | 6.3% | A substantial financial-institution position adds another institutional voting bloc. |
| State Street | 4.60M shares | 5.2% | Further reinforces dispersed institutional control. |
| CEO Michael Metzger | 1.97M shares and exercisable options | 2.2% | Creates material personal exposure without giving the CEO voting control. |
| All directors and executive officers | 4.43M shares and exercisable options | 4.8% | Management alignment is meaningful but subordinate to external institutions. |
Incentives emphasize product execution
The board included seven directors in the 2026 proxy, with six independent members and the CEO as the only non-independent director. Four standing committees covered audit, compensation, nominating and governance, and science and technology. The science committee is especially relevant because oversight must evaluate trial design, portfolio priorities and technical risk.
What risks and KPIs matter most for Syndax?
A small number of products, indications, clinical readouts and financing assumptions drive most of Syndax’s value. Key indicators must connect adoption with cash consumption and pipeline probability, not just revenue growth.
Commercial and clinical execution risks are tightly linked
The largest risks appear in ordinary operating line items
Clinical setbacks can strand R&D investment and prolong losses. Competition can slow prescriptions, increase discounts or raise selling costs; supply disruption can interrupt availability. Safety findings may change use or monitoring. Because eligibility depends on biology and prior treatment, addressable populations may also prove smaller than estimated.
Why does Syndax’s business model matter for valuation?
Syndax requires a product-by-product, probability-adjusted DCF because current cash flow is negative and much of long-term value depends on label expansion. The model should separate Revuforj direct economics from Niktimvo profit-sharing economics, then treat new indications and new assets as distinct risk-adjusted scenarios.
The DCF should be built around patient and cash-flow mechanics
Sensitivity is concentrated in a few assumptions
Terminal value deserves caution. Rare-disease pricing, exclusivity and physician adoption can support attractive economics, but competition can compress price and duration. Use explicit product forecasts through exclusivity and a conservative terminal assumption. Reconcile enterprise value to equity value with cash, the royalty-financing liability and fully diluted shares.
What is the key takeaway from Syndax Pharmaceuticals analysis?
Syndax is a focused commercial biotechnology company at an inflection point. The company has already cleared the hardest binary hurdle for two programs—FDA approval—and Q1 2026 showed rapid revenue growth, narrowing losses and lower cash burn. Revuforj now supplies most reported revenue, while Niktimvo contributes a partner-leveraged profit stream. That gives Syndax more validation than a development-stage biotech, but less diversification and cash-flow certainty than established pharma.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.